Acumen Pharmaceuticals (ABOS) Competitors

$2.39 -0.10 (-4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 -0.01 (-0.21%)

As of 06:44 PM Eastern

ABOS vs. AVTE, CTMX, SLDB, TLRY, and ARVN

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Aerovate Therapeutics (AVTE), CytomX Therapeutics (CTMX), Solid Biosciences (SLDB), Tilray Brands (TLRY), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

In the previous week, Acumen Pharmaceuticals had 10 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 10 mentions for Acumen Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 0.55 beat Aerovate Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Positive
Aerovate Therapeutics	Neutral

Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Acumen Pharmaceuticals currently has a consensus price target of $6.67, suggesting a potential upside of 178.94%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Acumen Pharmaceuticals beats Aerovate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

CytomX Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.44	-$17.37M	-$0.41	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

In the previous week, CytomX Therapeutics had 9 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 19 mentions for CytomX Therapeutics and 10 mentions for Acumen Pharmaceuticals. CytomX Therapeutics' average media sentiment score of 0.75 beat Acumen Pharmaceuticals' score of 0.55 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics presently has a consensus price target of $12.78, suggesting a potential upside of 238.04%. Acumen Pharmaceuticals has a consensus price target of $6.67, suggesting a potential upside of 178.94%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CytomX Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

CytomX Therapeutics beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Solid Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Acumen Pharmaceuticals and 8 mentions for Solid Biosciences. Acumen Pharmaceuticals' average media sentiment score of 0.55 beat Solid Biosciences' score of -0.31 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences currently has a consensus target price of $16.36, suggesting a potential upside of 114.46%. Acumen Pharmaceuticals has a consensus target price of $6.67, suggesting a potential upside of 178.94%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solid Biosciences' return on equity of -73.42% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Solid Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by company insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Solid Biosciences beats Acumen Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Acumen Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.78	-$2.19B	-$13.65	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

In the previous week, Tilray Brands had 4 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 14 mentions for Tilray Brands and 10 mentions for Acumen Pharmaceuticals. Tilray Brands' average media sentiment score of 0.81 beat Acumen Pharmaceuticals' score of 0.55 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tilray Brands has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Tilray Brands currently has a consensus target price of $11.50, indicating a potential upside of 109.09%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 178.94%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Tilray Brands and Acumen Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

In the previous week, Arvinas had 16 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 26 mentions for Arvinas and 10 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.55 beat Arvinas' score of 0.49 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Arvinas currently has a consensus target price of $15.14, indicating a potential upside of 60.75%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 178.94%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arvinas has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arvinas has higher revenue and earnings than Acumen Pharmaceuticals. Arvinas is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.31	-$80.80M	-$3.32	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

Summary

Arvinas beats Acumen Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$179.85M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-1.28	18.47	20.90	25.61
Price / Sales	N/A	296.18	549.93	78.79
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	1.98	6.93	9.93	6.96
Net Income	-$121.33M	$24.11M	$3.55B	$333.52M
7 Day Performance	-3.24%	0.08%	-0.33%	0.45%
1 Month Performance	-10.82%	0.84%	1.34%	4.06%
1 Year Performance	143.88%	78.10%	41.10%	36.24%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.2266 of 5 stars	$2.39 -4.0%	$6.67 +178.9%	+137.1%	$179.85M	N/A	N/A	20	News Coverage Earnings Report
AVTE Aerovate Therapeutics	N/A	$24.52 +1.2%	N/A	+194.1%	$710.71M	N/A	N/A	20	High Trading Volume
CTMX CytomX Therapeutics	2.7884 of 5 stars	$4.09 -2.3%	$13.44 +229.1%	+51.6%	$695.21M	$76.20M	N/A	170	Trending News Earnings Report Analyst Forecast Analyst Revision
SLDB Solid Biosciences	2.9037 of 5 stars	$6.82 -5.7%	$16.09 +135.9%	+164.5%	$671.18M	N/A	N/A	100	News Coverage Earnings Report Analyst Forecast
TLRY Tilray Brands	3.5481 of 5 stars	$5.72 -3.1%	$11.50 +101.2%	+21.2%	$665.96M	$210.48M	N/A	2,842

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. AVTE, CTMX, SLDB, TLRY, and ARVN

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Summary

How does Acumen Pharmaceuticals compare to Tilray Brands?

Summary

How does Acumen Pharmaceuticals compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. AVTE, CTMX, SLDB, TLRY, and ARVN

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Does the media favor ABOS or AVTE?

Which has more volatility and risk, ABOS or AVTE?

Which has higher valuation & earnings, ABOS or AVTE?

Do institutionals & insiders hold more shares of ABOS or AVTE?

Is ABOS or AVTE more profitable?

Do analysts rate ABOS or AVTE?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Which has preferable earnings & valuation, CTMX or ABOS?

Is CTMX or ABOS more profitable?

Which has more risk and volatility, CTMX or ABOS?

Does the media prefer CTMX or ABOS?

Do analysts prefer CTMX or ABOS?

Do insiders and institutionals believe in CTMX or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Which has better valuation and earnings, SLDB or ABOS?

Does the media favor SLDB or ABOS?

Do analysts recommend SLDB or ABOS?

Is SLDB or ABOS more profitable?

Which has more volatility & risk, SLDB or ABOS?

Do insiders and institutionals hold more shares of SLDB or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Tilray Brands?

Which has higher valuation and earnings, TLRY or ABOS?

Does the media refer more to TLRY or ABOS?

Do institutionals and insiders believe in TLRY or ABOS?

Which has more risk and volatility, TLRY or ABOS?

Is TLRY or ABOS more profitable?

Do analysts rate TLRY or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Arvinas?

Does the media refer more to ARVN or ABOS?

Is ARVN or ABOS more profitable?

Do analysts rate ARVN or ABOS?

Which has more risk and volatility, ARVN or ABOS?

Do institutionals and insiders believe in ARVN or ABOS?

Which has higher valuation and earnings, ARVN or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools